The INVITE-Home Study will give patients more options for how they can get Cabenuva, a Long-Acting Injectable antiretroviral therapy (LAI-ART). Instead of going into a doctor’s office once a month, study participants will choose a friend or family member to learn how to administer the medication from the comfort of their homes. This study will address a critical need to develop alternative and decentralized LAI-ART delivery methods that can mitigate barriers to uptake and persistence, enhance the real-world LAI-ART effectiveness, reduce systemic and structural inequities, address clinical and policy challenges, and close key gaps in HIV care.
In collaboration with funders at the Centers for Disease Control and Prevention. UCSF researchers on the INVITE-Home Study will conduct the study in 2 parts:
In Aim 1, we will design and develop an innovative treatment buddy training to improve the acceptability and uptake of LAI-ART at home. We will interview PWH, treatment buddies, and clinicians to develop the training. In these interviews, we will evaluate the needs of all these participants as well as the complications they may encounter.
In Aim 2, we will enhance our understanding of home-based LAI-ART using the training developed in Aim 1. We will do this by examining the implementation and effectiveness of home-based LAI-ART injections.
